Navigation Links
MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
Date:9/6/2007

Tuesday, September 11, 2007 - 11:00 a.m. ET; 8:00 a.m. PT

VANCOUVER and SAN DIEGO, CA, Sept. 6 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, will host a conference call and webcast on Tuesday, September 11, 2007 at 11:00 a.m. ET (8:00 a.m. PT) to discuss financial results for the first fiscal quarter ended July 31, 2007. An update on company activities will also be provided. To participate in the conference call, please dial 416-644-3415 or 1-800-732-9303. The call will be available for replay until September 25, 2007 by calling 416-640-1917 or 1-877-289-8525 and entering the pass code 21244947 followed by the number sign. The live and archived webcast can be accessed through the company's website at http://www.migenix.com for the next 90 days.

MIGENIX will also be hosting its 2007 Annual General Meeting of the shareholders of the Company on Monday, September 10, 2007 at 2:00 p.m. Pacific Time at the BC Research Complex, Auditorium, 3650 Wesbrook Mall, Vancouver, British Columbia.

About MIGENIX

MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs primarily in the area of infectious diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C infections (Phase II and preclinical), the prevention of catheter-related infections (Phase III) and the treatment of dermatological diseases (Phase II). MIGENIX is headquartered in Vancouver, British Columbia, Canada with US operations in San Diego, California. Additional information can be found at http://www.migenix.com.

"Jim DeMesa"

James M. DeMesa, M.D.

President & CEO

CONTACT: Art Ayres, MIGENIX Inc., Tel: (604) 221-9666 Ext. 233, aayres@migenix.com; Dian Griesel, Ph.D., Inves
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. The Genesis of Gendicine: The Story Behind the First Gene Therapy
2. Midwest life science stocks sizzle in a tepid first quarter
3. Morgridge Institute for Research seeks first CEO
4. Sonic Foundry reports first cash-positive quarter
5. Angel investors commit $12.7B in first half of `06
6. Aurora team implants Wisconsins first total artificial heart
7. First half of 2006 roundup: Big Pharma trumps biotech
8. GE announces first installation of Discovery VCT
9. GE Healthcare enjoys robust growth in first quarter
10. Madison asks for wireless bids; airport, downtown would be first
11. Tech Digest: Inacom, PKWare at Infosecurity, Firstlogic, Teklynx
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... ... a Silicon Valley-based CRO specializing in Clinical Trial Management. CSSi LifeSciences is ... services. The core expertise of PRC Clinical is focused on Clinical Trial Management, ...
(Date:7/29/2015)... MA (PRWEB) , ... July 29, 2015 , ... Nearly ... of serious diseases. Yet few people realize that a rich source of these cells ... young adults, and teeth that need to be pulled to make room for braces. ...
(Date:7/28/2015)... 2015 People with a common form of ... and sometimes profound improvements in their hearing and understanding ... a new multicenter study led by specialists at NYU ... online ahead of print in the journal The Laryngoscope July ... in the United States implanted ...
(Date:7/28/2015)... ... 28, 2015 , ... VetStem Biopharma will be offering weekly private guided tours ... area veterinarians. , The tour and course will be given every Wednesday at 6pm ... Poway facility. Staff members are welcome to attend with their veterinarian as well. Participants ...
Breaking Biology Technology:CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Advanced Oral and Maxillofacial Surgery (AOMS) in Elmhurst, IL Partners with Provia Labs to make Store-A-Toothâ„¢ Dental Stem Cell Banking Available to their Patients 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 3VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2
... 19, 2012 RayBiotech, Inc. today announced that it ... core facilities at academic and government research institutes in ... the partnership program, core diagnostics facilities will be able ... component of their current services offerings at no cost ...
... 19, 2012  New data presented today studied the ... nitric oxide (NO) to patients being evaluated for ... privately held, advanced development-stage technology company, announced that ... Right Heart Catheterization (RHC) in subjects being evaluated ...
... Childhood obesity is a widespread global epidemic ... (NAFLD) [2] is now the leading cause of liver ... Liver Congress™ 2012 furthers this concern by showing that childhood ... the most common form of liver cancer [3] - ...
Cached Biology Technology:RayBiotech, Inc. Announces New Diagnostic Core Facility Partnering Program 2New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation 2New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation 3New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation 4Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood 2Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood 3Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood 4
(Date:7/8/2015)... July 8, 2015 Summary Pancreatic cancer ... fourth most fatal, with a mortality rate of 10.9 ... of pancreatic cancer patients has highlighted a significant need ... not being met by the current market. A ... products with varying molecule types and mechanisms of action, ...
(Date:7/8/2015)... 8, 2015  Trovagene, Inc. (NASDAQ: TROV ... announced the launch of a study that aims ... Monitoring℠ (PCM) technology for predicting response to treatment ... combination of the novel immunotherapy agents Yervoy® (ipilumumab), ... inhibitor. The 50-patient study will be led by ...
(Date:7/7/2015)... DUBLIN , June 30, 2015 ... ) has announced the addition of the ... their offering. To this date, fingerprint ... biometric technology and fingerprint sensors are well developed. ... capacitive sensing technology. The domain of ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... by researchers at Queen Mary University of London collates data ... per cent of the births in England and Wales. Examples ... neural tube defects such as spina bifida, and limb malformations ... (PHE), the study is the most up-to-date and comprehensive of ...
... and the American Society for Cell Biology (ASCB) announced a ... ( LSE ). This partnership adds to GSA,s ... resources and research to its members and the public. ... in the life sciences and is renowned for its data-driven ...
... led by Charles D. Nichols, PhD, Associate Professor of ... successfully translated a new technology to better study behaviors ... tool Designer Receptors Exclusively Activated by Designer ... dose-dependently remotely control behaviors and physiological processes in the ...
Cached Biology News:1 baby in every 46 born with a congenital anomaly says new report 2Genetics Society of America joins editorial partnership for CBE-Life Sciences Education 2LSUHSC researchers develop new system to better study behavior, cell function 2
... The Model 175 tube gel cell is ... gels for 2-D electrophoresis applications. The upper ... OD tubes 9-23 cm long for isoelectric ... upper buffer chamber and cooling core, lower ...
... In Situ Apoptosis Detection Kit detects ... indirect TUNEL method, utilizing an anti-digoxigenin ... Fluorescein reporter molecule. It provides indirect ... are analyzed using either flow cytometry ...
... agarose is specifically for electrofocusing. ... and is recommended for electrofocusing ... proteins or complexes that are ... molecular sieving in polyacrylamide gels. ...
... The BioGenex VISION Sytem is ... that comes with proprietary digital imaging ... for digital image acquisition, analysis, archving/retrieval ... VISION comes with the industry's fastest ...
Biology Products: